Gansu Longshenrongfa Pharmaceutical IndustryLTD Past Earnings Performance
Past criteria checks 3/6
Gansu Longshenrongfa Pharmaceutical IndustryLTD has been growing earnings at an average annual rate of 53.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 36.4% per year. Gansu Longshenrongfa Pharmaceutical IndustryLTD's return on equity is 11.5%, and it has net margins of 6.1%.
Key information
53.9%
Earnings growth rate
53.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 36.4% |
| Return on equity | 11.5% |
| Net Margin | 6.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Gansu Longshenrongfa Pharmaceutical IndustryLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,039 | 64 | 555 | 28 |
| 31 Dec 23 | 1,080 | 62 | 560 | 30 |
| 30 Sep 23 | 824 | 57 | 396 | 14 |
| 30 Jun 23 | 728 | 50 | 326 | 15 |
| 31 Mar 23 | 593 | 43 | 222 | 10 |
| 31 Dec 22 | 413 | 26 | 128 | 9 |
| 30 Sep 22 | 522 | 15 | 211 | 19 |
| 30 Jun 22 | 457 | -1 | 186 | 13 |
| 31 Mar 22 | 356 | -6 | 138 | 10 |
| 01 Jan 22 | 288 | -9 | 91 | 7 |
| 30 Sep 21 | 254 | 6 | 81 | 6 |
| 30 Jun 21 | 267 | 13 | 77 | 6 |
| 31 Mar 21 | 256 | 2 | 77 | 6 |
| 31 Dec 20 | 255 | 2 | 76 | 6 |
| 30 Sep 20 | 245 | -5 | 71 | 8 |
| 30 Jun 20 | 224 | -6 | 70 | 8 |
| 31 Mar 20 | 229 | 6 | 64 | 8 |
| 31 Dec 19 | 239 | 13 | 68 | 7 |
| 30 Sep 19 | 212 | 7 | 71 | 7 |
| 30 Jun 19 | 203 | 10 | 69 | 7 |
| 31 Mar 19 | 203 | 13 | 68 | 7 |
| 31 Dec 18 | 203 | 12 | 67 | 7 |
| 30 Sep 18 | 230 | 15 | 65 | 5 |
| 30 Jun 18 | 250 | 14 | 65 | 8 |
| 31 Mar 18 | 270 | 16 | 68 | 7 |
| 31 Dec 17 | 270 | 17 | 65 | 6 |
| 30 Sep 17 | 274 | 23 | 65 | 4 |
| 30 Jun 17 | 277 | 37 | 57 | 0 |
| 31 Mar 17 | 281 | 45 | 51 | 0 |
| 31 Dec 16 | 270 | 47 | 46 | 0 |
| 30 Sep 16 | 278 | 55 | 40 | 0 |
| 31 Dec 15 | 277 | 61 | 34 | 0 |
| 31 Dec 14 | 302 | 60 | 32 | 0 |
| 31 Dec 13 | 275 | 41 | 27 | 0 |
Quality Earnings: 300534 has high quality earnings.
Growing Profit Margin: 300534's current net profit margins (6.1%) are lower than last year (7.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300534's earnings have grown significantly by 53.9% per year over the past 5 years.
Accelerating Growth: 300534's earnings growth over the past year (49%) is below its 5-year average (53.9% per year).
Earnings vs Industry: 300534 earnings growth over the past year (49%) exceeded the Pharmaceuticals industry -0.01%.
Return on Equity
High ROE: 300534's Return on Equity (11.5%) is considered low.